BUCKINGHAMSHIRE, U.K. and PISCATAWAY, N.J., Nov. 19, 2003 (PRIMEZONE) -- Amersham Biosciences, the life sciences business of Amersham (LSE:AHM) (NYSE:AHM) (OSE:AHM), has enhanced its CodeLink(TM) Informatics Solution to help scientists to improve productivity further by streamlining data extraction, acquisition and management processes in their gene expression experiments. The suite of tools includes CodeLink Expression Analysis software, new workflows added to the Scierra(TM) Microarray Laboratory Workflow System (LWS) and compatibility with Scierra LWS DiscoveryHub(TM) platform.
Combined in the CodeLink Informatics Solution, is a powerful data management tool for the CodeLink Gene Expression System enabling researchers to produce, capture and integrate experimental data. The CodeLink Expression Analysis Software has been developed as an automated application for acquiring gene expression values from CodeLink Bioarray images allowing users to process images from multiple CodeLink validated scanners. It also provides data output compatible with commonly used downstream data analysis applications including Rosetta Resolver(TM) and Luminator(TM), GeneSpring(TM), SpotFire(TM), GeneSight(TM) and dChip.
The updated Scierra Microarray LWS offers complete data management for the CodeLink bioarray workflow. It has additional data management capabilities and is compatible with one-color and two-color pre-arrayed slide products, as well as multiple brands of scanners and third party analysis software. Scierra Microarray LWS tracks the progress of samples through target preparation, hybridisation, slide processing, image acquisition and expression analysis. This open system is also MIAME/MAGE and FDA Regulation 21 CFR Part 11 compliant.
With the addition of Scierra LWS DiscoveryHub, scientists will be able to quickly integrate their data generated by CodeLink and Scierra Microarray LWS with any third party data, public data, in-house data, clinical data, algorithms and applications.
"This total informatics solution for CodeLink experiments will mean scientists carrying out gene expression experiments have access to produce, capture and integrate data quickly and easily," comments John Schneider, Vice President of Informatics Marketing at Amersham Biosciences. "With the ability to streamline the data extraction, acquisition and management processes using the CodeLink Informatics Solution, researchers will be able to dramatically increase the efficiency of their basic drug discovery and research programmes."
Amersham Biosciences, the life sciences business of Amersham (LSE: NYSE: OSE: AHM), is a world leader in developing and providing integrated systems and solutions for disease research, drug development and manufacture. Our systems are used to uncover the function of genes and proteins, for the discovery and development of drugs and for the manufacture of biopharmaceuticals. The customers for Amersham Biosciences' products and technology are pharmaceutical and biotechnology companies and research and academic institutions, principally in North America, Europe, Latin America and Asia. More information about Amersham Biosciences is available at www.amershambiosciences.com
Amersham Biosciences-enabling molecular medicine
This information is provided by RNS
The company news service from the London Stock Exchange